• Agenus priced an oversubscribed private placement targeting USD 85 million upfront gross proceeds, with up to USD 255 million more from warrant exercises.
• Deal includes 23,035,227 common shares or pre-funded warrants, with Series A warrants for 21,144,277 shares at USD 4.02.
• Also issued Series B warrants for 33,797,214 shares at USD 5.03; combined gross proceeds could reach USD 340 million.
• Proceeds earmarked to fund the registrational Phase 3 ROBBIN neoadjuvant BOT+BAL trial in MSS colon cancer, extending runway through year-end 2031 if fully exercised.
• Placement expected to close around July 15, 2026; board to expand to nine with two Class III seats designated by Commodore Capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.